• Markets
    • icon
  • Companies
ACL · ASX

Australian Clinical Labs Ltd (ASX:ACL)

AU$2.67

 0.0 (0.0%)
ASX:Live
06/12/2023 04:10:05 PM
HALO Small HALO Ords HALO Capital Efficiency GROWTH AUS Consensus Cheap +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ACL Overview

ACL Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About ACL

Website

N/A

Telephone

61.13.0045.3688

Address

1868-1892 Dandenong Road Clayton, Victoria (VIC) 3168

Description

Australian Clinical Labs Ltd. engages in the provision of pathology services. It operates through the Pathology segment. The Pathology segment includes pathology/clinical laboratory services provided in Australia. The company was founded in 2015 and is headquartered in Clayton, Australia.

ACL Price Chart

Key Stats

Market Cap

AU$532.84M

PE

15.50

EV/EBITDA

3.5

Dividends Overview

DIV Yield

4.2%

Franking

100%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 2.47 - 3.87

Trade Value (12mth)

AU$450,394.00

1 week

1.91%

1 month

0.38%

YTD

-8.25%

1 year

-17.34%

All time high

6.39

Key Fundamentals

EPS 3 yr Growth

-12.200%

EBITDA Margin

25.80%

Operating Cashflow

$144m

Free Cash Flow Return

36.50%

ROIC

9.10%

Interest Coverage

12.90

Quick Ratio

0.50

Other Data

Shares on Issue (Fully Dilluted)

201m

HALO Sector

Healthcare

Next Company Report Date

22-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

6.52

ACL Announcements

Latest Announcements

Date Announcements

31 October 23

Becoming a substantial holder from AEF

×

Becoming a substantial holder from AEF

29 March 23

TOV: HLS Panel Receives Application

×

TOV: HLS Panel Receives Application

29 March 23

Change in substantial holding

×

Change in substantial holding

29 March 23

Change in substantial holding

×

Change in substantial holding

28 March 23

Update - Dividend/Distribution - ACL

×

Update - Dividend/Distribution - ACL

28 February 22

Change of Director's Interest Notice

×

Change of Director's Interest Notice

28 August 23

Becoming a substantial holder

×

Becoming a substantial holder

28 April 22

Change of Director's Interest Notice

×

Change of Director's Interest Notice

28 April 22

Change of Director's Interest Notice

×

Change of Director's Interest Notice

28 April 22

Change of Director's Interest Notice

×

Change of Director's Interest Notice

27 September 22

Change of Director's Interest Notice

×

Change of Director's Interest Notice

27 October 22

Medlab Pathology Cyber Incident

×

Medlab Pathology Cyber Incident

27 March 23

HLS: Directors' Statement re Takeover

×

HLS: Directors' Statement re Takeover

27 March 23

Suspension of DRP

×

Suspension of DRP

27 March 23

Becoming a substantial holder

×

Becoming a substantial holder

26 August 22

Change in substantial holding

×

Change in substantial holding

26 August 21

FY21 financial results investor presentation

×

FY21 financial results investor presentation

24 September 21

Annual Report to shareholders

×

Annual Report to shareholders

24 September 21

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

24 February 22

Appendix 4D

×

Appendix 4D

24 February 22

Media Release - 1H22 Financial Results

×

Media Release - 1H22 Financial Results

24 February 22

1H22 Investor Presentation

×

1H22 Investor Presentation

24 February 22

Dividend/Distribution - ACL

×

Dividend/Distribution - ACL

24 February 22

Establishment of Dividend Reinvestment Plan

×

Establishment of Dividend Reinvestment Plan

23 October 23

2023 AGM - Chair and CEO Address

×

2023 AGM - Chair and CEO Address

23 October 23

2023 AGM results

×

2023 AGM results

23 May 23

HLS: Directors' Statement re Takeover

×

HLS: Directors' Statement re Takeover

23 May 22

Presentation to ASA Conference

×

Presentation to ASA Conference

ACL Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock 0.40 0.89 0.18 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock 0.40 0.88 0.18 Lock Lock Lock
     Growth % Lock Lock Lock Lock 94.7 123.0 -79.8 Lock Lock Lock
     PE X Lock Lock Lock Lock 9.4 5.4 15.5 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 4.0 2.6 3.5 Lock Lock Lock
CFPS $ Lock Lock Lock Lock 0.70 1.47 0.75 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock 0.67 1.18 0.20 Lock Lock Lock
     Growth % Lock Lock Lock Lock 24.6 110.2 -49.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock 19.8 25.8 5.8 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.12 0.53 0.14 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A 341.7 -73.6 Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.8 5.8 4.2 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 30 60 78 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.41 1.16 0.86 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock -0.15 0.33 0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -193.5 317.3 -89.2 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 152 201 201 Lock Lock Lock
Basic m Lock Lock Lock Lock 152 201 201 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 641 989 692 Lock Lock Lock
     Growth % Lock Lock Lock Lock 31.5 54.3 -30.0 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 61 94 94 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 184 362 146 Lock Lock Lock
     Growth % Lock Lock Lock Lock 116.4 96.5 -59.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock 28.7 36.6 21.1 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 71 63 79 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock 211 374 179 Lock Lock Lock
     Growth % Lock Lock Lock Lock 125.5 77.4 -52.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock 32.8 37.8 25.8 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 88 106 123 Lock Lock Lock
EBIT $m Lock Lock Lock Lock 123 268 56 Lock Lock Lock
     Growth % Lock Lock Lock Lock 689.4 118.3 -79.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock 19.1 27.1 8.1 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock 87 255 48 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 26 76 12 Lock Lock Lock
Net Income $m Lock Lock Lock Lock 60 178 36 Lock Lock Lock
     Growth % Lock Lock Lock Lock 46.3 195.2 -79.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock 9.4 18.0 5.2 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock 154 284 144 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 10 21 7 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -6 -72 -12 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock -147 -221 -138 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock 144 263 137 Lock Lock Lock
     Growth % Lock Lock Lock Lock 56.3 82.1 -48.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock 0.2 0.3 0.2 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 12 70 47 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 36 28 21 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 484 628 579 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 234 168 215 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock 268 235 296 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 402 395 406 Lock Lock Lock
Equity $m Lock Lock Lock Lock 82 232 172 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 316 400 388 Lock Lock Lock
     Growth % Lock Lock Lock Lock 39.2 26.7 -3.1 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock 12.5 28.4 6.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 73.7 76.7 20.8 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock 31.8 61.5 11.4 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock 19.1 50.5 9.1 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock 48.7 80.5 36.5 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock 9.6 31.8 12.9 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.3 0.6 1.7 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock 326.7 101.0 171.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 0.7 0.6 0.6 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 0.6 0.5 0.5 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 31.0 19.3 17.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock 92.8 126.2 76.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 10.2 12.8 8.3 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 34.2 37.5 31.1 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 2.9 2.7 2.6 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 1.3 1.6 1.2 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 1.3 1.6 1.2 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 13.5 25.8 7.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 17.9 40.6 8.3 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 30.3 30.0 25.4 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock 12.5 28.4 6.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 5.9 2.7 3.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 73.7 76.7 20.8 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 69.8 40.1 21.8 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock 51.4 30.8 4.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 10.7 9.7 11.8 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 35.8 28.4 43.8 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 46.5 38.2 55.6 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 14.8 12.5 15.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 31.7 25.6 40.6 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

4.2%

Franking Level

100%

DPSg

-73.58%

Quality Yield

Lock

Falling Divs over next 2

Lock

Expected Dividend Cashflow

Dividend Clarity,
Enhanced
Strategy

Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

6.52%

Value ($M)

34

Prior Change

0.20%

7 Day Change

0.30%

1 Month Change

-0.30%

3 Month Change

-0.40%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ACL Shortsell

Frequently Asked Questions

The current share price of Australian Clinical Labs Ltd (ACL:ASX) is AU$2.67.
The 52-week high share price for Australian Clinical Labs Ltd (ACL:ASX) is AU$3.87.
The 52-week low share price for Australian Clinical Labs Ltd (ACL:ASX)? is AU$2.47.
The current TTM dividend payout for Australian Clinical Labs Ltd (ACL:ASX) is 4.20.
The last dividend payment of Australian Clinical Labs Ltd (ACL:ASX) is AU$0.07.
Australian Clinical Labs Ltd (ACL:ASX) has a franking level of 100%.
Australian Clinical Labs Ltd (ACL:ASX) is classified in the Healthcare.
The current P/E ratio for Australian Clinical Labs Ltd (ACL:ASX) is 15.50.
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.